Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

← catalyst calendar

NCT06039384

Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →. With Mirati Therapeutics Inc..

Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
6actual
Sites
14
Countries
Italy, Spain, United Kingdom +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

This was a strategic business decision. There were no safety concerns contributing to this decision.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-12-28actualWhen the study began enrolling
Primary completion2025-04-11actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-07-11actualThe whole study's end, after follow-up
First posted2023-09-15actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-08-03actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Advanced Solid Tumors

Interventions

  • Drug: INCB099280
  • Drug: adagrasib — also filed as KRAZATI

Primary outcomes

what the primary-completion date above is the date OF
Part 1: Number of participants with Dose Limiting Toxicities (DLTs)
measured Up to 28 days
Number of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 2 years and 90 days
Number of participants with TEAEs leading to dose modification or discontinuation
measured Up to 2 years and 90 days

Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed